CLDX — Celldex Therapeutics Share Price
0.000.00%
Last trade - 00:00- $1.30bn
- $573.86m
- $7.02m
- 42
- 14
- 44
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.74 | ||
| Price to Tang. Book | 1.8 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 185.06 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -25.91% | ||
| Return on Equity | -26.84% | ||
| Operating Margin | -2778.89% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7.42 | 4.65 | 2.36 | 6.88 | 7.02 | 3.67 | 3.33 | 14.46% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Directors
- Karen Shoos NEC (67)
- Anthony Marucci CEO (59)
- Sam Martin CFO (50)
- Tibor Keler EVP (62)
- Freddy Jimenez SVP (52)
- Sarah Cavanaugh SVP (46)
- Elizabeth Crowley SVP (49)
- Margo Heath-Chiozzi SVP (64)
- Ronald Pepin SVP (65)
- Richard Wright SVP (57)
- Diane Young SVP (65)
- Keith Brownlie IND (68)
- Herbert Conrad IND (88)
- James Marino IND (71)
- Harry Penner IND (75)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 9th, 1983
- Public Since
- May 15th, 1986
- No. of Shareholders
- 136
- No. of Employees
- 186
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 66,384,191
- Address
- 53 Frontage Road, Suite 220, HAMPTON, 08827
- Web
- https://celldex.com/
- Phone
- +1 9082007500
- Contact
- Sarah Cavanaugh
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for CLDX
Celldex Therapeutics Inc Annual Shareholders Meeting
Celldex Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Celldex Therapeutics Inc Earnings Release
Similar to CLDX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Celldex Therapeutics share price?
As of Today at 19:50 UTC, shares in Celldex Therapeutics are trading at $19.57. This share price information is delayed by 15 minutes.
How has the Celldex Therapeutics share price performed this year?
Shares in Celldex Therapeutics last closed at $19.57 and the price had moved by -46.03% over the past 365 days. In terms of relative price strength the Celldex Therapeutics share price has underperformed the S&P500 Index by -50.18% over the past year.
What are the analyst and broker recommendations for Celldex Therapeutics?
The overall consensus recommendation for Celldex Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Celldex Therapeutics dividend yield?
Celldex Therapeutics does not currently pay a dividend.
Does Celldex Therapeutics pay a dividend?
Celldex Therapeutics does not currently pay a dividend.
When does Celldex Therapeutics next pay dividends?
Celldex Therapeutics does not currently pay a dividend.
How do I buy Celldex Therapeutics shares?
To buy shares in Celldex Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Celldex Therapeutics?
As of the previous close price of $19.57, shares in Celldex Therapeutics had a market capitalisation of $1.30bn.
Where are Celldex Therapeutics shares listed?
Here are the trading details for Celldex Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CLDX
What kind of share is Celldex Therapeutics?
Based on an overall assessment of its quality, value and momentum Celldex Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Celldex Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Celldex Therapeutics is $62.08. That is 217.22% above the last closing price of $19.57.
Analysts covering Celldex Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.28 for the next financial year.
Find out moreWhat is the trend in the Celldex Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celldex Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -23.46%.
As of the last closing price of $19.57, shares in Celldex Therapeutics were trading -30.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Celldex Therapeutics PE Ratio?
The Celldex Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $19.57.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Celldex Therapeutics?
Celldex Therapeutics' management team is headed by:
- Karen Shoos - NEC
- Anthony Marucci - CEO
- Sam Martin - CFO
- Tibor Keler - EVP
- Freddy Jimenez - SVP
- Sarah Cavanaugh - SVP
- Elizabeth Crowley - SVP
- Margo Heath-Chiozzi - SVP
- Ronald Pepin - SVP
- Richard Wright - SVP
- Diane Young - SVP
- Keith Brownlie - IND
- Herbert Conrad - IND
- James Marino - IND
- Harry Penner - IND